United Therapeutics (UTHR) Cash Flow Statement

Click line-items for a historical chart and %

Net income
Depreciation and amortization	23.8M
Provisions for bad debt and inventory obsolescence
Deferred tax expense
Share-based compensation	-93.2M
Amortization of debt discount and debt issue costs
Amortization of discount or premium on investments
Equity loss in affiliate and other
Excess tax benefits from share-based compensation	-4.6M
Accounts receivable	-31.7M
Inventories	-12.9M
Prepaid expenses
Other assets
Accounts payable
Accrued expenses
Other liabilities
Net cash provided by operating activities
Purchases of property, plant and equipment	-23.3M
Purchases of held-to-maturity investments	-800K
Maturities of held-to-maturity investments	78.8M
Redemptions of trading investments
Restrictions on cash
Net cash (used in) provided by investing activities
Proceeds from the exercise of stock options	6.2M
Excess tax benefits from share-based compensation	4.6M
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase in cash and cash equivalents	121.2M
Cash and cash equivalents, beginning of period	831.8M
Cash and cash equivalents, end of period	953M
Cash paid for interest	100K
Cash paid for income taxes	283.7M
Non-cash investing activity: non-cash additions to property, plant and equipment	3.2M

Entities mentioned with UTHR

View All Entities